Clinical Trial

Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study

Enrolling by Invitation Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The treatment options for advanced HER2-negative breast cancer are limited. The single or combined drug therapy has a short remission time. Moreover, after multiple lines of treatment, patients are often in an awkward situation of "no more drugs available". And through literature research, it has been found that there is a synergistic effect between immunotherapy and anti-angiogenic therapy, as well as between radiotherapy and immunotherapy. This study will provide new approaches for the treatment of advanced HER2-negative breast cancer in the second-line setting, and offer new evidence-based medical evidence for patients with advanced HER2-negative breast cancer in the era of immunotherapy.
Trial Details
NCT Number NCT06890871
Lead Sponsor Zhongnan Hospital
Conditions Breast Cancer, Metastatic Breast Cancer
Enrollment 25 participants
Start Date 2024-08-08
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-24